1
|
Human Papillomavirus Genotypes Infecting the Anal Canal and Cervix in HIV+ Men and Women, Anal Cytology, and Risk Factors for Anal Infection. Pathogens 2023; 12:pathogens12020252. [PMID: 36839524 PMCID: PMC9963202 DOI: 10.3390/pathogens12020252] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 01/24/2023] [Accepted: 01/27/2023] [Indexed: 02/08/2023] Open
Abstract
The incidence of anal intraepithelial neoplasias associated with HPV is rising worldwide. In the general population, this pathology is rare, but individuals living with HIV/AIDS are at a significantly higher risk. We aimed to study HPV infection and performed cytological screening to study the epidemiological and behavioral determinants in a group of men and women living with HIV from a region in Mexico with high HIV incidence. This was a cross-sectional study including adults living with HIV/AIDS performed in Merida (Mexico). We invited patients of public HIV/STD clinics and those affiliated with social organizations of people living with HIV to participate in the study. Participants responded to an instrument to assess their risky behaviors and clinical history. Swabs from the anal canal and cervix and anal cytology specimens were obtained by medical staff from women and by self-sampling from men. For the 200 participants, 169 men and 31 women, anal HPV PCR tests resulted in 59.8% positivity (62.6% of men and 45.2% of women), and 17 genotypes were identified. The most frequent high-risk (HR) types for the anal canal were: HPV33 (35.3%), HPV58 (20.6%), HPV66 (18.6%), HPV45 (17.6%), and HPV16 (14.7%). Multiple genotypes were found in over 80% of the participants. Receptive anal intercourse in the previous 12 months, inconsistent condom use, and detectable HIV titers (≥50 cc/mL) were associated with HPV infection (p < 0.05). Cytology (smears and liquid-based) identified that 34.6% of the participants had low-grade squamous intraepithelial lesions (LSILs), and 3.5% had high-grade squamous intraepithelial lesions (HSILs). Neither HPV nor lesions were associated with low CD4+ counts (<200 cells/mm3, p > 0.05). Of the women, 60% were infected in the cervix and 45% in the anal canal, with an agreement of at least one genotype in 90%. The HR-HPV types associated with HSILs were HPV66, 33, 52, 51, 45, 18, and 68.
Collapse
|
2
|
Poynten IM, Jin F, Molano M, Machalek DA, Roberts JM, Hillman RJ, Cornall A, Phillips S, Templeton DJ, Law C, Fairley CK, Grulich AE, Garland SM. Comparison of four assays for human papillomavirus detection in the anal canal. Clin Microbiol Infect 2022; 28:1652.e1-1652.e6. [PMID: 35809783 DOI: 10.1016/j.cmi.2022.06.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2022] [Revised: 06/24/2022] [Accepted: 06/28/2022] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Anal cancer is preceded by high-risk human papillomavirus (HRHPV) infection, predominantly HPV16. No HPV assay is licenced for use in anal screening. We aimed to determine the sensitivity and specificity of four anal canal swab HPV assays to predict high grade squamous epithelial lesions (HSIL). METHODS In a cohort of Australian HIV-positive and negative gay and bisexual men, we compared the sensitivity and specificity of detection of 13 anal HRHPV genotypes by Linear Array (LA), Cobas 4800, EuroArray and Anyplex II HPV28 (+ and ++ cut offs), compared their ability to predict prevalent anal HSIL and compared anal canal HRHPV detection with HRHPV isolated from HSIL using laser capture microdissection (LCM). RESULTS A total of 475 participants had baseline results available for all 4 assays (166, 35.0% HIV positive), and 169 participants had a diagnosis of cytological and/or histological HSIL.HPV16 and any HRHPV detection were highest with Anyplex II HPV28 (+) (156, 32.8% 95% CI 28.6-37.2 and 359, 75.6%, 95% CI 71.5-79.4 respectively). For detection of concurrent HSIL and HPV16, the assay sensitivity was similar ranging from 49.1%, 95% CI 41.4-56.9 (Anyplex II HPV28 ++) to 55.0%, 95% CI 47.2-62.7 (Anyplex II HPV28 +). For concurrent HSIL and any HRHPV detection, EuroArray was more specific than Anyplex II HPV28 (+) (45.9% 95% CI 40.2-51.7 vs 36.7%, 95% CI 31.3-42.4, p=0.021) and had comparable specificity with Anyplex II HPV28 (++) (45.9% vs 47.2%, 95% CI 41.5-53.0, p=0.75). All assays had high sensitivities for predicting HPV16 detected on LCM (92.5-97.5%). Anyplex II HPV28 and EuroArray were significantly more sensitive than LA for lesions caused by non-HPV16 HRHPV types on LCM. CONCLUSION Anyplex II HPV28 and EuroArray detected more non-16 HRHPV genotypes than LA. Increasing the Anyplex II HPV28 cut off improved specificity, without compromising sensitivity for detection of concurrent HSIL.
Collapse
Affiliation(s)
- I Mary Poynten
- The Kirby Institute, Wallace Wurth Building, University of New South Wales, Kensington, Sydney, New South Wales 2052, Australia.
| | - Fengyi Jin
- The Kirby Institute, Wallace Wurth Building, University of New South Wales, Kensington, Sydney, New South Wales 2052, Australia
| | - Monica Molano
- Centre for Women's Infectious Diseases, The Royal Women's Hospital, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia; Molecular Microbiology, Murdoch Children's Research Institute, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia
| | - Dorothy A Machalek
- The Kirby Institute, Wallace Wurth Building, University of New South Wales, Kensington, Sydney, New South Wales 2052, Australia; Centre for Women's Infectious Diseases, The Royal Women's Hospital, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia; Molecular Microbiology, Murdoch Children's Research Institute, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia
| | - Jennifer M Roberts
- Douglas Hanly Moir Pathology, 14 Giffnock Ave, Macquarie Park, Sydney, New South, Wales 2113, Australia
| | - Richard J Hillman
- St Vincent's Hospital, 390 Victoria St, Darlinghurst, Sydney, New South Wales 2010, Australia
| | - Alyssa Cornall
- Centre for Women's Infectious Diseases, The Royal Women's Hospital, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia; Molecular Microbiology, Murdoch Children's Research Institute, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia
| | - Samuel Phillips
- Centre for Women's Infectious Diseases, The Royal Women's Hospital, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia; Molecular Microbiology, Murdoch Children's Research Institute, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia
| | - David J Templeton
- Department of Sexual Health Medicine, Sydney Local Health District, 16 Marsden St, Camperdown, Sydney, New South Wales 2050, Australia; Sydney Medical School, University of Sydney, Sydney, New South Wales 2006, Australia
| | - Carmella Law
- St Vincent's Hospital, 390 Victoria St, Darlinghurst, Sydney, New South Wales 2010, Australia
| | | | - Andrew E Grulich
- The Kirby Institute, Wallace Wurth Building, University of New South Wales, Kensington, Sydney, New South Wales 2052, Australia
| | - Suzanne M Garland
- Centre for Women's Infectious Diseases, The Royal Women's Hospital, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia; Molecular Microbiology, Murdoch Children's Research Institute, Flemington Rd, Parkville, Melbourne, Victoria 3052, Australia; Department of Obstetrics and Gynaecology, University of Melbourne, Grattan St, Parkville, Melbourne, Victoria 3052, Australia
| | | |
Collapse
|